43 - Lipid and lipoprotein metabolism: Miscellaneous| Volume 235, ISSUE 2, e205, August 2014

Different association of serum docosahexaenoic acid and eicosapentaenoic acid levels with atherogenic and anti-atherogenic lipoproteins in statin-treated diabetes patients

      Objectives: Supplementation of purified n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been shown to reduce cardiovascular risk beyond low-density lipoprotein cholesterol (LDL-C). However, regarding the circulating levels of PUFAs, despite anti-atherogenic features of EPA, there is controversy about those of DHA. In this study, we aimed to clarify the difference in the clinical association with atherogenic or anti-atherogenic lipoproteins between circulating EPA and DHA levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect